Effect of Hautriwaic Acid Isolated from Dodonaea viscosa in a Model of Kaolin/Carrageenan-Induced Monoarthritis

Abstract

In the present work, the antiarthritic activity of hautriwaic acid is reported. This ent-clerodane diterpene isolated from Dodonaea viscosa was evaluated in mice using a kaolin/carrageenan-induced monoarthritis model. The inflammation observed in the joint (knee) on days 1–8 ranged from 50–70 %. After 10 days of treatment with different doses of hautriwaic acid (5, 10, 20 mg/kg), a decrease in knee inflammation was detected. This recovery was observed with both reference drugs, methotrexate (1 mg/kg) and diclofenac (0.75 mg/kg). In these groups of mice, the concentration of proinflammatory cytokines interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha in the joint was significantly lower than that of the negative control group (animals with damage without any treatment). The negative control group presented a decrease in the concentration of interleukin-10, while the groups that received hautriwaic acid at different dose exhibited an increase in this interleukin. This anti-inflammatory cytokine was not modified in the joint of mice with diclofenac, but in mice that received methotrexate, a significant decrease was observed. Hautriwaic acid isolated from D. viscosa diminished the joint edema induced by this mixture of polysaccharides (carrageenan), possibly by acting as immunomodulator of the inflammatory response.

Key words

Dodonaea viscosa - Sapindaceae - hautriwaic acid - clerodane - arthritis - kaolin/carrageenan

• References

• 1 Murphy G, Caplice N, Molloy M. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology 2008; 47: 1446-1451
• 2 Aguillón JC, Cruzat A, Contreras J, Dotte A, Pesce B, Aravena O, Salazar L, Catalán D, Abello P, Aguirre A, Llanos C, Cuchacovich M. Artículo de Revisión: Terapias emergentes en artritis reumatoide. Rev Med Chile 2005; 133: 969-976
• 3 Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-2179
• 4 Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Almazor MS, Bridges SL, Chatham WW, Hochberg M, Maclean C, Mikuls T, Moreland LW, OʼDell J, Turkiewicz A, Furst DE. American college of rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 2008; 59: 762-784
• 5 Maldonado A, Ortiz S, Dorado O. Preparados galénicos e imágenes de plantas medicinales, una alternativa para promotoras de la salud en la reserva de la biosfera sierra de Huautla. Cuernavaca, Morelos: Universidad Autónoma del Estado de Morelos, Centro de Educación Ambiental e Investigación Sierra de Huautla; 2004: 7-11
• 6 Dorado O, Maldonado B, Arias D, Sorani V, Ramírez R, Leyva E, Valenzuela D. Programa de conservación y manejo reserva de la biosfera sierra de Huautla. Morelos, México: Comisión Nacional de Áreas Naturales Protegidas; 2005: 3-4 33–34, 54, 139–170
• 7 Rajamanickam V, Rajasekaran A, Anandarajagopal K, Sridharan D, Selvakumar K, Rathinaraj BS. Anti-diarrheal activity of Dodonaea viscosa root extracts. Int J Pharm Bio Sci 2010; 1: 182-185
• 8 Anilreddy B. Preparation, characterization and biological evaluation of some overview of Dodonea viscosa Linn. J Pharm Sci Technol 2009; 1: 1-9
• 9 Khurranm M, Khan MA, Hameed A, Abbas N, Qayum A, Inayat H. Antibacterial activities of Dodonaea viscosa using contact bioautography technique. Molecules 2009; 14: 1332-1341
• 10 Pengelly A. Medicinal activity of Dodonaea viscosa. A preliminary study. Newcastle, Australia: RIRDC; 2008. Available at http://www.rirde.gov.au Accessed June 15, 2011
• 11 Khalil NM, Sperotto JS, Manfron MP. Antiinflammatory activity and acute toxicity of Dodonaea viscosa . Fitoterapia 2006; 77: 478-480
• 12 Arun M, Asha VV. Gastroprotective effects of Dodonaea viscosa on various experimental ulcer models. J Ethnopharmacol 2008; 118: 460-465
• 13 Alagarsamy V, Venket-Narayanan R, Thangathirupathy A, Amuthalakshmi S, Slvakamisundari P, Jubie S, Syed-Ali AKS, Suresh M. Antiinflammatory activity of Dodonaea viscosa Linn leaf extracts. Indian Drugs 2007; 44: 559-560
• 14 Sachdev K, Kulshreshtha DK. Flavonoids from Dodonaea viscosa . Phytochemistry 1983; 22: 1253-1256
• 15 Mata R, Contreras JL, Crisanto D, Pereda-Miranda R, Castañeda P, Del Rio F. Chemical studies on Mexican plants used in traditional medicine, XVIII. New secondary metabolites from Dodonaea viscosa . J Nat Prod 1991; 54: 913-917
• 16 Ortega A, García PE, Cárdenas J, Mancera C, Marquina S, Garduño ML, Maldonado E. Methyl dodonates, a new type of diterpenes with a modified clerodane skeleton from Dodonaea viscosa . Tetrahedron 2001; 57: 2981-2989
• 17 Niu HM, Zeng DQ, Long CL, Peng YH, Wang YH, Luo JF, Wang HS, Shi YN, Tang GH, Zhao FW. Clerodane diterpenoids and prenylated flavonoids from Dodonaea viscosa . J Asian Nat Prod Res 2010; 12: 7-14
• 18 Salinas-Sánchez DO, Herrera-Ruiz M, Pérez S, Jiménez-Ferrer E, Zamilpa A. Anti-inflammatory activity of hautriwaic acid isolated from Dodonaea viscosa leaves. Molecules 2012; 17: 4292-4299
• 19 Hamid A, Nurul K, Akhtar M, Mohammad RS, Syed GM, Naveed I, Said N. Hautriwaic acid as one the hepatoprotective constituent of Dodonaea viscosa . Phytomedicine 2014; 21: 131-140
• 20 Berin C, Buell MG. Phorbol myristate acetate ex vivo model of enhanced colonic epithelial permeability. Digest Dis and Sci 1995; 40: 2268-2279
• 21 Uzkeser H, Cadirci E, Halici Z, Odabasoglu F, Polat B, Yuksel TN, Atalay F. Anti-inflammatory and antinociceptive effects of salbutamol on acute and chronic models of inflammation in rats: involvement of an antioxidant mechanism. Mediators Inflamm 2012; 2012: 438912
• 22 Hsü HY, Chen YP. Structure of hautriwaic acid. Phytochemistry 1971; 10: 2813-2814
• 23 Arriaga FJ, Wollenweber E, Schober I, Dostal P, Braun S. 2β-hydroxyhautriwaic acid, a clerodane type ditepenoid and other terpenoids from three Baccharis species . Phytochemistry 1986; 25: 719-721
• 24 Neugebauer V, Han JS, Adwanikar H, Fu Y, Ji G. Techniques for assessing knee joint pain in arthritis. Mol Pain 2007; 3: 1-13
• 25 Daniel LW, Sciorra VA, Ghosh S. Phospholipase D, tumor promoters, proliferation and prostaglandins. Biochim Biophys Acta 1999; 1439: 265-276
• 26 Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 2012; 4: a006049
• 27 Chung HJ, Lee HS, Shin JS, Lee SH, Park BM, Youn YS, Lee SK. Modulation of acute and chronic inflammatory processes by a traditional medicine preparation GCSB-5 both in vitro and in vivo animal models. J Ethnopharmacol 2010; 130: 450-459
• 28 Liew FY. TH1 and TH2 cells: a historical perspective. Nat Rev Immunol 2002; 2: 55-60
• 29 Fielding CA, Jones GW, McLoughlin RM, McLeod L, Hammond VJ, Uceda J, Williams AS, Lambie M, Foster TL, Liao CT, Rice CM, Greenhill CJ, Colmont CS, Hams E, Coles B, Kift-Morgan A, Newton Z, Craig KJ, Williams JD, Williams GT, Davies SJ, Humphreys IR, OʼDonnell VB, Taylor PR, Jenkins BJ, Topley N, Jones SA. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 2014; 40: 40-50
• 30 Yarilina A, Xu K, Chan C, Ivashkiv LB. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum 2012; 64: 3856-3866
• 31 Yun YC, Koo ST, Kim CH, Lyu Y, Grady JJ, Chung JM. Two variables that can be used as pain indices in experimental animal models of arthritis. J Neurosci Meth 2002; 115: 107-113
• 32 De Lima FO, Alves V, Filho JM, Da Silva Almeida JR, Rodrigues LC, Soares MB, Villarreal CF. Antinociceptive effect of lupeol: evidence for a role of cytokines inhibition. Phytother Res 2013; 27: 1557-1563
• 33 Ritter AM, Dominicano TP, Verri Jr. WA, Zarpelon AC, Da Silva LG, Barbosa CP, Natali MR, Cuman RK, Bersani-Amado CA. Antihypernociceptive activity of anethole in experimental inflammatory pain. Inflammopharmacology 2012; 21: 187-197
• 34 Balkwill F, Joffroy C. TNF: a tumor suppressing factor or a tumor-promoting factor?. Future Oncol 2010; 6: 1833-1836
• 35 Iwakura Y. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev 2002; 13: 341-355
• 36 Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23: 1-21
• 37 Jazayeri JA, Carroll GJ, Vernallis AB. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists. Int Immunopharmacol 2010; 10: 1-8
• 38 Sabat R, Grütz G, Warszawska K, Warszawska K, Kirsch S, Witte EK, Wolk K, Geginat J. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331-344
• 39 Moore KW, De Waal MR, Coffman RL, OʼGarra A. Interleukin-10 and interleukin 10 receptor. Annu Rev Immunol 2001; 19: 683-765
• 40 Kuklinski C. Farmacognosia/estudio de las drogas y sustancias medicamentosas de origen natural. Barcelona: Ediciones Omega S. A.; 2000: 33
• 41 Wagner H, Bladt S. Plant drug analysis. A thin layer chromatography atlas. 2nd. edition. Munich: Springer; 2009: 362
• 42 Hartmann P, Szabó A, Erős G, Gurabi D, Horváth G, Németh I, Ghyczy M, Boros M. Anti-inflammatory effects of phosphatidylcholine in neutrophil leukocyte-dependent acute arthritis in rats. Eur J Pharmacol 2009; 622: 58-64
• 43 Sluka KA, Bailey K, Bogush J, Olson R, Ricketts A. Treatment with either high or low frequency TENS reduces the secondary hyperalgesia observed after injection of kaolin and carrageenan into the knee joint. Pain 1998; 77: 97-102